S. Miknyoczki

发表

Animal models of disease: pre-clinical animal models of cancer and their applications and utility in drug discovery.

B. Ruggeri, Faye Camp, S. Miknyoczki, 2014, Biochemical pharmacology.

Discovery of small molecule c-Met inhibitors: Evolution and profiles of clinical candidates.

S. Miknyoczki, T. Herbertz, T. Underiner, 2010, Anti-cancer agents in medicinal chemistry.

The Trk tyrosine kinase inhibitor CEP-701 (KT-5555) exhibits significant antitumor efficacy in preclinical xenograft models of human pancreatic ductal adenocarcinoma.

A. Klein-Szanto, B. Ruggeri, S. Miknyoczki, 1999, Clinical cancer research : an official journal of the American Association for Cancer Research.

Pan-trk inhibition decreases metastasis and enhances host survival in experimental models as a result of its selective induction of apoptosis of prostate cancer cells.

A. Weeraratna, J. Isaacs, S. Miknyoczki, 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.

Neurotrophins and Trk receptors in human pancreatic ductal adenocarcinoma: Expression patterns and effects on In vitro invasive behavior

B. Ruggeri, S. Miknyoczki, A. Klein-Szanto, 1999, International journal of cancer.

Role of neurotrophin-trk interactions in oncology: the anti-tumor efficacy of potent and selective trk tyrosine kinase inhibitors in pre-clinical tumor models.

B. Ruggeri, S. Miknyoczki, J. Singh, 1999, Current medicinal chemistry.

The selective poly(ADP-ribose) polymerase-1(2) inhibitor, CEP-8983, increases the sensitivity of chemoresistant tumor cells to temozolomide and irinotecan but does not potentiate myelotoxicity

Allison L. Zulli, R. Parchment, B. Ruggeri, 2007, Molecular Cancer Therapeutics.

Chemopreventive activity of Oltipraz against N-nitrosobis(2-oxopropyl)amine (BOP)-induced ductal pancreatic carcinoma development and effects on survival of Syrian golden hamsters.

B. Ruggeri, S. Miknyoczki, K. Leahy, 1995, Carcinogenesis.

The neurotrophin-trk receptor axes are critical for the growth and progression of human prostatic carcinoma and pancreatic ductal adenocarcinoma xenografts in nude mice.

P. Dobrzanski, B. Ruggeri, S. Miknyoczki, 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.

Chemopotentiation of temozolomide, irinotecan, and cisplatin activity by CEP-6800, a poly(ADP-ribose) polymerase inhibitor.

B. Ruggeri, S. Miknyoczki, Sheila J Miknyoczki, 2003, Molecular cancer therapeutics.

Synthesis and biological profile of the pan-vascular endothelial growth factor receptor/tyrosine kinase with immunoglobulin and epidermal growth factor-like homology domains 2 (VEGF-R/TIE-2) inhibitor 11-(2-methylpropyl)-12,13-dihydro-2-methyl-8-(pyrimidin-2-ylamino)-4H-indazolo[5,4-a]pyrrolo[3,4-c]

Allison L. Zulli, E. Bacon, B. Ruggeri, 2012, Journal of medicinal chemistry.

Vascular endothelial growth factor mediates vasogenic edema in acute lead encephalopathy

J. Laterra, B. Ruggeri, S. Miknyoczki, 2004, Annals of neurology.

The development and pharmacology of proteasome inhibitors for the management and treatment of cancer.

A. Hui, B. Ruggeri, S. Miknyoczki, 2009, Advances in pharmacology.

Stable reintroduction of wild-type P53 (MTmp53ts) causes the induction of apoptosis and neuroendocrine-like differentiation in human ductal pancreatic carcinoma cells

B. Ruggeri, S. Miknyoczki, Lingyi Huang, 1998, Oncogene.

The Novel Trk Receptor Tyrosine Kinase Inhibitor CEP‐701 (KT‐5555) Exhibits Antitumor Efficacy against Human Pancreatic Carcinoma (Panc1) Xenograft Growth and In Vivo Invasiveness

B. Ruggeri, S. Miknyoczki, Andres J Klein-Szanto, 1999, Annals of the New York Academy of Sciences.

Design and synthesis of dihydroindazolo[5,4-a]pyrrolo[3,4-c]carbazole oximes as potent dual inhibitors of TIE-2 and VEGF-R2 receptor tyrosine kinases.

Allison L. Zulli, E. Bacon, B. Ruggeri, 2008, Bioorganic & medicinal chemistry letters.

Improvement in oral bioavailability of 2,4-diaminopyrimidine c-Met inhibitors by incorporation of a 3-amidobenzazepin-2-one group.

K. L. Milkiewicz, S. Miknyoczki, T. Underiner, 2011, Bioorganic & medicinal chemistry.

Animal models of disease: pre-clinical animal models of cancer and their applications and utility in drug discovery.

B. Ruggeri, Faye Camp, S. Miknyoczki, 2014, Biochemical pharmacology.

Neurotrophin-Trk receptor interactions in neoplasia: a possible role in interstitial and perineural invasion in ductal pancreatic cancer.

B. Ruggeri, S. Miknyoczki, Andres J Klein-Szanto, 1996, Critical reviews in oncogenesis.